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Inhaled glucocorticosteroids decrease hydrogen
peroxide level in expired air condensate
in asthmatic patients
A. ANTCZAK*, Z. KURMANOWSKA*, M. KASIELSKI* AND D. NOWAK{
*Department of Pneumonology and Allergology and {Department of Physiology, Medical University of Lodz,
Kopcinkiego St. 22, 90–153 Lodz, Poland.
H2O2 is elevated in the exhaled air condensate in several inflammatory disorders of the lung, including bronchial
asthma, and thus may reflect inflammatory processes in the airways. Exhaled H2O2 may be used to guide the anti-
inflammatory treatment of patients with asthma. Therefore in this study we analysed the eect of inhaled
glucocorticosteroid beclomethasone for 4 weeks on H2O2 level in the exhaled air condensate.
Seventeen asthmatics and 10 healthy subjects were included to the study. Eleven patients were given inhaled
beclomethasone and six were given placebo (3M Health Care). In all patients pulmonary function tests were
performed. H2O2 in the expired air condensate was measured spectrofluorimetically (homovanillic acid method).
Inhaled beclomethasone significantly decreased H2O2 in the expired air condensate in the active-treatment group,
with a fall from baseline on day 1 which remained on day 43 (follow-up) (P50?05). Exhaled H2O2 in the active-
treatment group was significantly lower than that in placebo group (P50?05). A negative correlation between H2O2
and forced expiratory volume in 1 sec (FEV1) on day 29 was observed.
The decrease in exhaled H2O2 in the active-treatment group was accompanied by an improvement in pulmonary
function tests results.
Inhaled glucocorticoids reduce the level of H2O2 in the expired air condensate of asthmatic patients over a 4-week
period and this may reflect their anti-inflammatory activity in lung diseases.
Key words: bronchial asthma; airway inflammation; hydrogen peroxide; expired air; breath condensate; inhaled
glucocorticosteroids.
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An important feature of bronchial asthma is the influx of
circulating phagocytes, including eosinophils, mast cells
and neutrophils, into the bronchial wall (1–3). After
activation they generate reactive oxygen species, including
hydrogen peroxide (H2O2), which can play an important
role in the development of lung damage and bronchial
hyperresponsiveness (4–8). It has been proved that neu-
trophils and eosinophils from both adult and children
asthmatic patients can generate increased amounts of O2ÿ
and H2O2 after challenge with phorbol esters and fMLP
than cells of matched healthy subjects (9–12). Moreover,
the ability of neutrophils isolated from asthmatics toReceived 18 January 1999 and accepted in revised form 6 May
1999.
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0954-6111/00/050416+06 $35?00/0produce superoxide anion correlated with the degree of
airway hyperresponsiveness to inhaled metacholine and
histamine (13). Furthermore, in asthematic children, the
generation of O2ÿ was at a significantly higher rate in
children who suered attacks than those who did not (13).
This is consistent with the observation that patients with
exacerbated asthma exhale more H2O2 than patients with
stable disease (14). H2O2 in the expired breath condensate
can be elevated in other lung inflammatory diseases — such
as chronic obstructive pulmonary disease (COPD), and
adult respiratory distress syndrome (ARDS) (15,16).
In asthmatic patients an increased level of H2O2 in the
expired breath condensate is positively correlated with an
increased level of lipid peroxidation products (thiobarbi-
turic acid reactive species) in the expired breath condensate
which proves oxidant/antioxidant imbalance in the airway
of these patients (17). An intense airway inflammation can
be caused either by H2O2 alone or a newly generated
hydroxyl radical (18).
Phagocytes are an important source of H2O2. It is
released in extracellular fluid and in the airways. H2O2# 2000 HARCOURT PUBLISHERS LTD
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can be excreted with expired air. Topical glucocorticoster-
oids are highly eective in the control of asthma and they
are now the first-line therapy in patients with persistent
symptoms. Their eectiveness in controlling asthma is
medicated by inhibiting the inflammatory process through
influence on inflammatory mediators (20–23). The induc-
tion of inducible nitiric oxide synthase can be inhibited by
glucocorticosteroids (24). This is consistent with studies of
Kharitonow et al. who have proved that inhaled gluco-
corticosteroids decrease nitric oxide in the exhaled air of
asthmatic patients (25). Steroids markedly reduce the
survival of inflammatory cells such as eosinophils by
inducing apoptosis (26). The eosinophil count in the
induced sputum of asthmatic children is positively corre-
lated with the NO level in expired air and the reduction of
survival rates of these cells could be responsible for the NO
decrease in expired air. Collection of the exhaled air
condensate provides a non-invasive method of obtaining
samples from the lower airways (27,28). Exhaled H2O2 may
be used instead as a diagnostic test to guide anti-
inflammatory treatment. Until now there has been no
double-blind, randomized clinical trial on the eect of
inhaled steroids on H2O2 level in expired air of asthmatic
patients. We have therefore studied the eect of inhaled
beclomethasone dipropionate at a low dose on the level of
H2O2 in the expired air condensate of steroid-naive
asthmatic patients.
Materials and Methods
STUDY POPULATION
Our study was associated with a 6 week, randomized,
double-blind, double-dummy, multicentre study on ecacy
of 400mg day71 chlorofluorocarbon-free beclomethasone
dipropionate, delivered as an extrafine aerosol in adults
with moderate asthma approved by the sponsor (3M
pharmaceuticals, Loughborough, England) and Local
Ethics Committee as safe and non-invasive. It included 17
asthmatic subjects (mean age 40+9 years., 11 males and
five females) who had not suered from any infectious
disease for the last 4 months (Table 1). Eleven patients wereTABLE 1. Characteristics of study population
Active treatment patients
Number 11
Age (years) 41?4+9
Sex (M:F) 9:2
FVC% 96?5+1?2
FEV1% 69?3+3?2
FEV1 reversibility (%) 28?4+11
Asthma duration (years) 6+9given inhaled HFA-beclomethasone dipropionate 400 mg
day71 or HFA-placebo. They were asked to visit the Clinic
on day 15, 29 and fulfil the follow-up visit at day 43 (Fig. 1).
At all visits lung function tests and collection of breath
condensate were performed. The drug dose used in this
study is lower than that recommended in current treatment
guidelines for moderate asthma, however we used reformu-
lated CFC-free propellant, hydrofluoroalkane 134a (HFA),
resulting in an extra fine aerosal which gives improved drug
delivery to the airways. The study of Matthys has provided
data that a daily dose of 400 mg HFA-beclomethasone (3M
Pharmaceuticals, Loughborough, England) provides eec-
tive control in patients with moderate asthma (29). They
were recruited from the Medical University Out-patient
Clinic register. Asthmatic subjects were asked to stop any
medication except short acting b-agonists (salbutamol or
fenoterol) and to come to the clinic after a 4 week washout
period to perform lung function tests. Bronchial asthma
was diagnosed on history of wheezing dyspnoea and
previous documentation of bronchodilator-induced bron-
chial reversibility measured as more than a 15% increase of
FEV1 and the presence of airway hyper-reactivity after
histamine challenge test with PC20 of less than 8mg ml
71
according to the method of Cockroft (30).
Pulmonary function FEV1 between 50% and 80% of
predicted value, and bronchial reversibility of at least 15%
were basic inclusion criteria. The other inclusion criteria
were the ability to stop therapy other than 2-agonist
therapy. The duration of bronchial asthma was 1–18 years,
mean 7+5 years. Nine subjects were atopic as revealed by
the presence of immediate positive response to more than
12 common aeroallergen extracts (Allergopharma, Joachim
Ganzer KG Reinbeck/Hamburg, Germany) in Poland.
Seven asthmatics had a positive skin prick test to house
dust. The criteria for definition of non-atopic status was the
absence of immediate response on prick test and no family
history of atopy. Spirometry was performed with Flowsc-
reen (Erich Jaeger GmbH&Co. Germany) equipped with
software compatible to American Thoracic Society stan-
dards (31). None of the women were pregnant as assayed by
urine pregnancy test (Clearview HCG, Unipath GmbH
Wesel, Germany) or took oral contraceptives. This study
was approved by the local Ethics Committee and informed
consent was obtained.Placebo patients Healthy control
6 10
37?3+8 43?5+5
2:4 6:4
92?5+6?8 97?5+6?7
67?1+4?2 94?9+5?1
27?3+8 2?9+4?3
7+5 —
FIG. 1. Increase in FEV1 in active-treatment group (*)
compared with placebo (*). Median FEV1 at day 43 was
significantly higher in HFA-beclomethasone treatment
group compared with placebo (2?32+0?78 vs.
1?56+0?10 l) (P50?05). Increase in FEF25–75 in the
active-treatment group (*) compared with placebo (*).
In active treatment group FEF25–75 on 43 was
significantly higher than FEF25–75 in placebo group
(1?69+0?92 vs. 0?71+?20 l/sec, P50?05). Changes in
exhaled H2O2 in HFA-beclomethasone group (*) and
placebo-patients (*). The fall from 0?57+0?25 mmol on
day 1 of the study to 0?33+0?10 mmol on day 29
(P50?05). The concentration of exhaled H2O2 in active-
treatment group remained stable on treatment days (1–29)
and follow up (day 43) and was significantly lower than
that in placebo group on all days (P50?05).
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The air condensate was collected in a tube installed in the
polystyrene foamed container filled with ice and salt as
previously described. At the end of collection 2–5ml
aliquots of condensate osmolality using an osmometer
800cl, Trident (Warsaw, Poland). The rest was stored at
7808C for not longer than 7 days until H2O2 measurement.
Our previous experiments have shown that samples of
expired breath condensate and 761071 M H2O2 solution,
under these conditions, remain stable after 14 days of
storage. Similarly, 5 nM H2O2 incubated in the device for
20min at 08C revealed no significant changes of ability to
react with homovanillic acid (28). All collections wereperformed between 9 and 11 am and patients were asked to
stop any medication 12 h before the visit.
MEASUREMENT OF HYDROGEN
PEROXIDE
The content of H2O2 in expired breath condensate was
determined according to the method of Ruch et al. (32).
Briefly, 600 ml of expired breath condensate was mixed with
600ml solution of HRP (1U ml71) containing 100mM
homovanillic acid and incubated for 60 min at 378C.
Afterwards the sample was mixed with 150 ml 0?1 M glycine–
NaOH buer (pH 12) with addition of 25mM EDTA and
transferred into microcuvette (PE 5200-4339). The homo-
vanilic acid oxidation product as a measure of the amount
of H2O2 was determined spectrofluorimetically using Perkin
Elmer Luminescence Spectrometr LS-50 (Norwalk, CT)
operating in the read mode. Slit widths were set at 10 nm for
both emission and excitation and the integrate time was
0?1 sec excitation was at 312 nm and emission was measured
at 420 nm. Readings were converted into nmol using
regression equation Y= (x-x0)67?64 (Y-nmol of H2O2 per
one sample of expired breath condensate, X-intensity of
emission at 420 nm expressed in arbitrary units, x0-intensity
of emission given by reference sample containing distilled
water instead of breath condensate) obtained fron three
series of calibration experiments with 19 increasing
(0?0125–25 mM) H2O2 concentrations. The confidence level
was 95% and the P-value was less than 0?03 and 0?0001 for
the constant and regression coecient, respectively. The
linear least square estimation was used for calculation of
the regression equation. The lower limit of H2O2 detection
was 83mM and the calibration curve was linear up to a
concentration 16?7 mM H2O2. Values of H2O2 concentra-
tions obtained in this study are dierent to those in our
previous work, in which we were using dierent sample
volumes and the concentrations were expressed in nmoles
per sample (17,29).
SATISTICAL ANALYSIS
Data obtained in this study were non-parametric and
therefore are expressed as the median+interquartile range.
Readings that gave results below the method sensitivities
(83 nmol H2O2) were assumed to be 0 nmol. The dierences
between results in group of placebo and active-treatment
subjects were determined by Mann–Whitney analysis based
on rank sums. The median FEV1, FEF25–75 and concentra-
tions of hydrogen peroxide between days were compared
using Mann–Whitney U test. A P-value less than 0?05 was
considered to be significant. A rank correlation and
pulmonary function tests. All calculations were performed
using Microsoft Excel Version 5?0 software.
Results
H2O2 was detected in 10 active-treatment patients and in
five patients in the placebo group. In one patient in each
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The baseline exhaled H2O2 was significantly higher in
asthmatic patients than in normal subjects (0?54+ 0?21mM
vs. 0?03+0?02 mM, P50?01) and this is consistent with our
previous results (17). There were no statistically significant
dierences in H2O2 concentration in exhaled air condensate
nor pulmonary function tests between active-treatment and
placebo group just before randomization on day 1.
Inhaled HFA-beclomethasone significantly decreased
exhaled H2O2 in active treatment group, with a fall from
0?57+21 mM on day 1 of the study to 0?18+0?15 mM on day
29 (P50?05) (Fig. 1). The biggest fall was observed between
day 1 and day 15 of the study (0?57+0?25mM vs.
0?23+0?11 mM, P50?05). The concentration of exhaled
H2O2 in active-treatment group remained decreased on
treatment days (1–29) and follow-up and was significantly
lower than that in placebo group (0?23+0?11 vs.
0?66+0?19 mM on day 15, 0?33+0?1 vs. 0?69+0?26mM on
day 29, and 0?18+0?15 vs. 0?69+0?21mM on day 43,
respectively, P50?05). There were no significant dierences
between males and females.
In the placebo group H2O2 remained stable over the
study with no statistically significant dierences between
days 1, 15, 29 and 43. However, there can be observed a big
variability in particular patients with no detectable H2O2
level at day 1 and relatively high H2O2 concentration on
days 15 and 29. In some patients a big variability in H2O2
concentration was observed, too. A negative correlation
was found between H2O2 in exhaled air concentration on
day 29 and FEV1 on that day in active treatment group
(r=7 0?63, P50?05) (Fig. 2).
The decrease in H2O2 concentration in expired breath
condensate was accompanied by an increase in pulmonary
function test results, however they were not statistically
significant. Median FEV1 on day 43 was significantly higher
in HFA-beclomethasone treatment group compared with
that in placebo group (0?32+0?78 vs. 1?56+0?10 l) (Fig. 1).
Similarly, in active treatment group FEF25–75 on day 43 was
significantly higher than FEF25–75 in placebo group
(1?69+0?0.92 vs. 0?71+0?20l/sec, P50?05) (Fig. 1).FIG. 2. Negative correlation between H2O2 concentration
in expired air and FEV1 on day 29 in active treatment
group (r=70?63, P50?05).Discussion
We have demonstrated that an inhaled glucocorticoid
significantly reduces the level of H2O2 in the expired air
condensate of asthmatic patients over a 4-week period and
that the decreased H2O2 concentration remains stable for 2-
week follow-up. These findings are compatible with the
hypothesis that the increase in exhaled H2O2 is due to
airway inflammation. H2O2 has been accepted as a marker
of airway inflammation as it can be produced by
inflammatory cells involved in mucosal inflammation in
asthmatic subjects (2,3). Moreover, stimulated macro-
phages from asthmatic patients produce more reactive
oxygen species than those from healthy subjects (33). H2O2
is elevated in expired air condensates in various inflamma-
tory lung disorders such as ARDS, acute hypoxaemic
respiratory failure, cigarette smoking and COPD. Dohlman
described an increased H2O2 level in expired air condensate
in a relatively small group of asthmatic children, mainly in
those with acute disease. In some of them glucocorticoster-
oids were administered and this resulted in decreased
exhaled H2O2 level (14). It is postulated, however that
inflammation may be present in symptom free asthmatics
(34) and as a result of this phenomenon elevated H2O2 in
stable asthmatics could be observed (35). Jobsis has
described in an open study a group of 66 children with
stable asthma, 41 of whom were receiving inhaled
cortiosteroids daily. There was a significant dierence in
median H2O2 concentration between asthmatics without
anti-inflammatory treatment and healthy controls
(P50?05). The dierence in median H2O2 concentration
in the corticosteroid group was smaller, pointing out the
association of inhaled steroid with lower exhaled H2O2
concentration in asthmatics. A study in ARDS patients
treated with corticosteroids showed a tendency towards
lower levels of H2O2 in the expired air condensate as
compared to steroid-naive ARDS patients (36).
We speculate that there are several mechanisms whereby
inhaled glucocorticosteroids may reduce exhaled H2O2.
Steroids inhibit the synthesis of pro-inflammatory cytokines
in inflammatory cells such as macrophages (20). This could
lead to decreased activity of NADH oxidase which is
speculated to be the main source of H2O2 in asthmatic
patients. It was proved that neutrophils from both adult
and children asthmatic patients can generate increased
amounts of O2ÿ and H2O2. A close relationship between
the opsonized zymosan-induced chemiluminescence of
neutrophils and bronchial hyper-reactivity to histamine in
asthmatic children can also be observed (13). Inhibition of
the H2O2-generating system by inhibiting the synthesis of
pro-inflammatory cytokines could be responsible for
decreased H2O2 level in exhaled air of asthmatic subjects.
Finally, steroids may reduce the number of activated cells
that release pro-inflammatory cytokines in the airways by
blocking their influx into the lung (26).
In this study we observed an improvement in lung
function test over the study, especially in small airways. A
negative correlation was found between H2O2 concentra-
tion in exhaled air on day 29 and FEV1 in active treatment
group. The bigger FEV1 increase the bigger H2O2 fall in
420 A. ANTCZAK ET AL.expired air. This could reflect anti-inflammatory action of
inhaled steroid. The smaller inflammation in the airways is
accompanied by lower H2O2 concentration in expired air
and improvement in pulmonary function results.
What is interesting is that pulmonary function tests in the
active treatment group were higher than the placebo group
but not statistically significant. This can be due to a small
population who completed H2O2 collection and finally were
included into our part of the whole trial. However, it was
proved in the whole study population that inhaled HFA-
beclomethasone dipropionate 400mg day71 gives improved
drug delivery to the airways and that active treatment
produces significant improvements compared with placebo
in evening, PEF, FEV1 and FEF25–75 thus providing an
ecient control of patients with moderate asthma (29). A
relatively low dose of anti-inflammatory medication was
able to significantly decrease H2O2 level in expired air. As
H2O2 is elevated in several lung inflammatory disorders
reflecting an oxidant overload in the airways; rather than a
diagnostic test, exhaled H2O2 may be used to monitor anti-
inflammatory treatment and estimate disease severity over
time within subjects.
This is the first double-blind, placebo-controlled study
investigating the eect of an inhaled glucocorticosteroid on
H2O2 level in expired air condensate. It is dicult to
demonstrate a clear dose-response eect of glucocorticos-
teroid in asthma and many patients are needed for such
studies because of the variability in the response between
dierent patients (37). It is possible that using H2O2 in
exhaled breath condensate as a dose-response to inhaled
steroids may be documented as a means of monitoring
anti-inflammatory action of the steroid additionally to
measurement of airway responsiveness or pulmonary
function, and thus may provide a non-invasive means to
monitor the control of airway inflammation in asthmatic
patients. However large fluctuations in levels of H2O2 occur
within individual subjects and therefore this might limit its
value.
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